- Home
- ZURA vs IIIV Comparison
ZURA vs IIIV Comparison
Compare ZURA & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | IIIV |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 427.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ZURA | IIIV |
|---|---|---|
| Price | $6.18 | $15.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $13.00 | ★ $33.20 |
| AVG Volume (30 Days) | ★ 1.5M | 488.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.05 |
| Revenue Next Year | N/A | $8.07 |
| P/E Ratio | ★ N/A | $69.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $15.57 |
| 52 Week High | $7.25 | $33.97 |
Technical Indicators
Market Signals| Indicator | ZURA | IIIV |
|---|---|---|
| Relative Strength Index (RSI) | 60.07 | 35.10 |
| Support Level | $5.22 | $15.59 |
| Resistance Level | $6.76 | $17.12 |
| Average True Range (ATR) | 0.41 | 0.67 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 47.98 | 12.67 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About IIIV i3 Verticals Inc.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.